BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 27665358)

  • 1. KIFC1 induces resistance to docetaxel and is associated with survival of patients with prostate cancer.
    Sekino Y; Oue N; Shigematsu Y; Ishikawa A; Sakamoto N; Sentani K; Teishima J; Matsubara A; Yasui W
    Urol Oncol; 2017 Jan; 35(1):31.e13-31.e20. PubMed ID: 27665358
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The role of testicular nuclear receptor 4 in chemo-resistance of docetaxel in castration-resistant prostate cancer.
    Chen B; Yu S; Ding X; Jing C; Xia L; Wang M; Matro E; Rehman F; Niu Y; Li G; Chang C
    Cancer Gene Ther; 2014 Oct; 21(10):411-5. PubMed ID: 25104727
    [TBL] [Abstract][Full Text] [Related]  

  • 3. NPRL2 promotes docetaxel chemoresistance in castration resistant prostate cancer cells by regulating autophagy through the mTOR pathway.
    Luo S; Shao L; Chen Z; Hu D; Jiang L; Tang W
    Exp Cell Res; 2020 May; 390(2):111981. PubMed ID: 32234375
    [TBL] [Abstract][Full Text] [Related]  

  • 4. EGFR mediates docetaxel resistance in human castration-resistant prostate cancer through the Akt-dependent expression of ABCB1 (MDR1).
    Hour TC; Chung SD; Kang WY; Lin YC; Chuang SJ; Huang AM; Wu WJ; Huang SP; Huang CY; Pu YS
    Arch Toxicol; 2015 Apr; 89(4):591-605. PubMed ID: 24888374
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Class III beta-tubulin expression predicts prostate tumor aggressiveness and patient response to docetaxel-based chemotherapy.
    Ploussard G; Terry S; Maillé P; Allory Y; Sirab N; Kheuang L; Soyeux P; Nicolaiew N; Coppolani E; Paule B; Salomon L; Culine S; Buttyan R; Vacherot F; de la Taille A
    Cancer Res; 2010 Nov; 70(22):9253-64. PubMed ID: 21045157
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Resistance to docetaxel in prostate cancer is associated with androgen receptor activation and loss of KDM5D expression.
    Komura K; Jeong SH; Hinohara K; Qu F; Wang X; Hiraki M; Azuma H; Lee GS; Kantoff PW; Sweeney CJ
    Proc Natl Acad Sci U S A; 2016 May; 113(22):6259-64. PubMed ID: 27185910
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Docetaxel-mediated autophagy promotes chemoresistance in castration-resistant prostate cancer cells by inhibiting STAT3.
    Hu F; Zhao Y; Yu Y; Fang JM; Cui R; Liu ZQ; Guo XL; Xu Q
    Cancer Lett; 2018 Mar; 416():24-30. PubMed ID: 29246644
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reversible lysine-specific demethylase 1 antagonist HCI-2509 inhibits growth and decreases c-MYC in castration- and docetaxel-resistant prostate cancer cells.
    Gupta S; Weston A; Bearrs J; Thode T; Neiss A; Soldi R; Sharma S
    Prostate Cancer Prostatic Dis; 2016 Dec; 19(4):349-357. PubMed ID: 27349498
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of kinesin motor protein KIFC1 by AZ82 induces multipolar mitosis and apoptosis in prostate cancer cell.
    Parvin A; Hao SL; Tan FQ; Yang WX
    Gene; 2020 Nov; 760():144989. PubMed ID: 32717307
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Epithelial-to-mesenchymal transition mediates docetaxel resistance and high risk of relapse in prostate cancer.
    Marín-Aguilera M; Codony-Servat J; Reig Ò; Lozano JJ; Fernández PL; Pereira MV; Jiménez N; Donovan M; Puig P; Mengual L; Bermudo R; Font A; Gallardo E; Ribal MJ; Alcaraz A; Gascón P; Mellado B
    Mol Cancer Ther; 2014 May; 13(5):1270-84. PubMed ID: 24659820
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Effects and Mechanism of YK-4-279 in Combination with Docetaxel on Prostate Cancer.
    Yu L; Wu X; Chen M; Huang H; He Y; Wang H; Li D; Du Z; Zhang K; Goodin S; Zheng X
    Int J Med Sci; 2017; 14(4):356-366. PubMed ID: 28553168
    [No Abstract]   [Full Text] [Related]  

  • 12. HepaCAM inhibits the malignant behavior of castration-resistant prostate cancer cells by downregulating Notch signaling and PF-3084014 (a γ-secretase inhibitor) partly reverses the resistance of refractory prostate cancer to docetaxel and enzalutamide in vitro.
    Du Z; Li L; Sun W; Wang X; Zhang Y; Chen Z; Yuan M; Quan Z; Liu N; Hao Y; Li T; Wang J; Luo C; Wu X
    Int J Oncol; 2018 Jul; 53(1):99-112. PubMed ID: 29658567
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel CIL-102 derivatives as potential therapeutic agents for docetaxel-resistant prostate cancer.
    Miller DR; Tzeng CC; Farmer T; Keller ET; Caplan S; Chen YS; Chen YL; Lin MF
    Cancer Lett; 2018 Nov; 436():96-108. PubMed ID: 30077739
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of FAK inhibitor VS-6063 (defactinib) on docetaxel efficacy in prostate cancer.
    Lin HM; Lee BY; Castillo L; Spielman C; Grogan J; Yeung NK; Kench JG; Stricker PD; Haynes AM; Centenera MM; Butler LM; Shreeve SM; Horvath LG; Daly RJ
    Prostate; 2018 Mar; 78(4):308-317. PubMed ID: 29314097
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting CDC25C, PLK1 and CHEK1 to overcome Docetaxel resistance induced by loss of LZTS1 in prostate cancer.
    Al Nakouzi N; Cotteret S; Commo F; Gaudin C; Rajpar S; Dessen P; Vielh P; Fizazi K; Chauchereau A
    Oncotarget; 2014 Feb; 5(3):667-78. PubMed ID: 24525428
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serum exosomal P-glycoprotein is a potential marker to diagnose docetaxel resistance and select a taxoid for patients with prostate cancer.
    Kato T; Mizutani K; Kameyama K; Kawakami K; Fujita Y; Nakane K; Kanimoto Y; Ehara H; Ito H; Seishima M; Deguchi T; Ito M
    Urol Oncol; 2015 Sep; 33(9):385.e15-20. PubMed ID: 26027763
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tumorspheres derived from prostate cancer cells possess chemoresistant and cancer stem cell properties.
    Zhang L; Jiao M; Li L; Wu D; Wu K; Li X; Zhu G; Dang Q; Wang X; Hsieh JT; He D
    J Cancer Res Clin Oncol; 2012 Apr; 138(4):675-86. PubMed ID: 22237455
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of docetaxel resistance genes in castration-resistant prostate cancer.
    Marín-Aguilera M; Codony-Servat J; Kalko SG; Fernández PL; Bermudo R; Buxo E; Ribal MJ; Gascón P; Mellado B
    Mol Cancer Ther; 2012 Feb; 11(2):329-39. PubMed ID: 22027694
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of ABCB1 expression overcomes acquired docetaxel resistance in prostate cancer.
    Zhu Y; Liu C; Nadiminty N; Lou W; Tummala R; Evans CP; Gao AC
    Mol Cancer Ther; 2013 Sep; 12(9):1829-36. PubMed ID: 23861346
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibiting autophagy overcomes docetaxel resistance in castration-resistant prostate cancer cells.
    Wang Q; He WY; Zeng YZ; Hossain A; Gou X
    Int Urol Nephrol; 2018 Apr; 50(4):675-686. PubMed ID: 29460131
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.